ArticleCellular oncology (Dordrecht, Netherlands)2026
DIO3 associates with sorting nexins and endosomal trafficking networks in ovarian cancer.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
puroposeType 3 iodothyronine deiodinase (DIO3) is a membrane-associated enzyme that inactivates thyroid hormones and promotes high-grade serous ovarian cancer (HGSOC) progression. Although DIO3 undergoes continuous recycling between the plasma membrane and endosomal compartments, the mechanisms governing its intracellular routing and functional stability remain unknown.
methodsWe used Human ovarian cancer cells (ES-2, OVCAR3, OVSAHO, KURAMOCHI, NCI/ADR (NAR)), ovarian cancer tumors and normal tissues from patients, immortalized fallopian tube cells (FT109, FT237 and FT282) and HEK293T cells. DIO3 was knocked-down (shRNA) or overexpressed (CRISPR activation system). Flow cytometry (cell counts and apoptosis assay), proteomics, co-immunoprecipitation, proximity ligation assay, confocal imaging in the presence of endosomal transport inhibitors, and AlphaFold-based structural modeling were performed.
resultsWe identify sorting nexins SNX2 and SNX6 as components of the DIO3 trafficking machinery in ovarian cancer. Computer-based structural analysis provide a potential interface for SNXs association, requiring intact linker and catalytic domains of DIO3. Studies in ovarian cancer cells suggest that SNX6 is linked with DIO3 progression through endosomal and Golgi compartments, whereas SNX2 is associated with its recycling to the plasma membrane via RAB11-positive vesicles. Disruption of these pathways destabilizes DIO3-SNXs colocalization and selectively impairs proliferation and survival of DIO3-overexpressing cells.
conclusionThese findings establish intracellular trafficking as a fundamental determinant of DIO3 stability and function and uncover sorting nexin-associated routing as a previously unrecognized dependency and therapeutic vulnerability in ovarian cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.